Detalles de la búsqueda
1.
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.
J Clin Oncol;
: JCO2400581, 2024 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38819031
2.
Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC.
JTO Clin Res Rep;
3(10): 100406, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36247019
3.
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
J Clin Oncol;
36(22): 2251-2258, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29768118
4.
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol;
36(14): 1405-1411, 2018 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29596029
5.
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Am J Hematol;
93(5): 607-614, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29352732
6.
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Cancer Res Treat;
50(3): 691-700, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28701030
7.
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
J Clin Oncol;
34(24): 2858-65, 2016 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-27022118
8.
5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study.
Cancer Manag Res;
7: 165-73, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26109878
9.
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
N Engl J Med;
371(23): 2167-77, 2014 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25470694
10.
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.
Clin Genitourin Cancer;
12(5): 317-24, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24806399
11.
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
J Clin Oncol;
32(2): 76-82, 2014 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24323035
12.
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
BJU Int;
114(6b): E25-E31, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24298897
13.
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
J Clin Oncol;
31(23): 2870-8, 2013 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-23857972
14.
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Breast Cancer Res Treat;
136(3): 759-67, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23073758
15.
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
J Clin Oncol;
23(22): 5126-37, 2005 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15983390
Resultados
1 -
15
de 15
1
Próxima >
>>